Abstract
The termindolent in describing a non-Hodgkin’s lymphoma (NHL) generally refers to a group of B-cell NHLs composed of predominantly small cells that make up several categories, including follicular lymphoma, small lymphocytic lymphoma, and lymphoma of mucosa-associated lymphoid tissue. Most patients with follicular lymphoma respond to therapy, and the average survival time in large series is approximately 10 years. Patients who achieve a complete remission with initial treatment have an approximately 25% chance of remaining free of disease for 10 years. However, this means that more than 80% of patients will require salvage therapy. Cladribine is a newer purine analogue and is of particular interest because it is resistant to deam-ination by adenosine deaminase. It is cytotoxic to both proliferating and resting lymphocytes, making it an attractive agent for the treatment of indolent NHL. In this review article, we summarize the current treatment approaches for indolent NHL and the results of cladribine monotherapy studies in Japan and cladribine studies in Germany that have focused on a combination therapy with mitoxantrone. Cladribine is a potent inhibitor of DNA repair. The combination of a DNA-damaging agent with an inhibitor of DNA repair constitutes the rationale for combining cladribine with mitoxantrone. A German study has demonstrated that the combination of reduced-dose cladribine and mitoxantrone is a highly active regimen with favorable toxicity profiles. Cladribine is highly effective as a single agent and in combination with mitoxantrone in the treatment of indolent NHL, and its availability broadens the range of therapeutic options for indolent NHL.
Similar content being viewed by others
References
Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting —Airlie House, Virginia, November 1997.J Clin Oncol. 1999;17: 3835–3849.
The International Non-Hodgkin’s Lymphoma Prognostic Factors Project: a predictive model for aggressive non-Hodgkin’s lymphoma.N Engl J Med. 1993;329:987–994.
Armitage JO, Weisenburger DD. New approach to classifying non- Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project.J Clin Oncol. 1998;16:2780–2795.
Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin’s lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin’s Lymphoma Classification Project.Ann Oncol. 1998;9:717–720.
The Non-Hodgkin’s Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma.Blood. 1997;89:3909–3918.
Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin’s lymphomas.N Engl J Med. 1984;311:1471–1475.
Mac Manus MP, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow- up study of patients treated at Stanford University.J Clin Oncol. 1996;14:1282–1290.
Wilder RB, Jones D, Tucker SL, et al. Long-term results with radiotherapy for stage I-II follicular lymphomas.Int J Radiat Oncol Biol Phys. 2001;51:1219–1227.
Gospodarowicz MK, Bush RS, Brown TC, Chua T. Prognostic factors in nodular lymphomas: a multivariate analysis based on the Princess Margaret Hospital experience.Int J Radiat Oncol Biol Phys. 1984;10:489–497.
Seymour JF, Cusack JD, Lerner SA, Pollock RE, Keating MJ. Case/ control study of the role of splenectomy in chronic lymphocytic leukemia.J Clin Oncol. 1997;15:52–60.
Gallagher CJ, Gregory WM, Jones AE, et al. Follicular lymphoma: prognostic factors for response and survival.J Clin Oncol. 1986;4:1470–1480.
McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.J Clin Oncol. 1998;16:2825–2833.
Hainsworth JD, Litchy S, Burris HA 3rd, et al. Rituximab as firstline and maintenance therapy for patients with indolent non-Hodgkin’s lymphoma.J Clin Oncol. 2002;20:4261–4267.
Ghielmini M, Hsu Schmitz S-F, Cogliatti S, et al. Prolonged treatment with rituximab significantly improves event free survival and duration of response in patients with follicular lymphoma: a randomised SAKK Trial [abstract].Blood. 2002;100:161a. Abstract 604.
Vose JM, Wahl RL, Saleh M, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin’s lymphomas.J Clin Oncol. 2000;18:1316–1323.
Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphoma.J Clin Oncol. 2002;20:3262–3269.
Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphomas.J Clin Oncol. 2001;19:3918–3928.
Czuczman MS. CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma.Semin Oncol. 1999;26(suppl 14):88–96.
Marcus R, Imrie K, Belch A, et al. An international multi-centre, randomized, open-label, phase III trial comparing rituximab added to CVP chemotherapy to CVP chemotherapy alone in untreated stage III/IV follicular non-Hodgkin’s lymphoma [abstract].Blood. 2003;102:28a. Abstract 87.
Byrd JC, Rai KR, Peterson BL, Appelbaum FR, Morrison VA, Kolitz JEA. The addition of rituximab to fludarabine significantly improves progression-free and overall survival in previously untreated chronic lymphocytic leukemia (CLL) patients [abstract].Blood. 2003;102:273a. Abstract 245.
Rohatiner AZ, Gregory WM, Peterson BA, Smalley RV. A meta- analysis of randomized trials evaluating the role of interferon as treatment for follicular lymphoma [abstract].Proc Am Soc Clin Oncol. 1998;17:4a. Abstract 11.
Bierman PJ, Vose JM, Anderson JR, Bishop MR, Kessinger A, Armitage JO. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin’s lymphoma.J Clin Oncol. 1997;15:445–450.
Freedman AS, Neuberg D, Mauch P, et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma.Blood. 1999;94:3325–3333.
Bierman PJ. Allogeneic bone marrow transplantation for lymphoma.Blood Rev. 2000;14:1–13.
Vose JM, Bierman PJ, Weisenburger DD, et al. Autologous hematopoietic stem cell transplantation for mantle cell lymphoma.Biol Blood Marrow Transplant. 2000;6:640–645.
Horning SJ, Negrin RS, Hoppe RT, et al. High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial.Blood. 2001;97:404–409.
O’Connor OA, Wright J, Moskowitz C, Macgregor-Cortelli B, Straus D, Horse-Grant D. Phase II clinical experience with the pro- teasome inhibitor bortezomib (formerly PS-341) in patients with indolent lymphoma [abstract].Proc Am Soc Clin Oncol. 2003;22: 2566. Abstract 2277.
Webb A, Cunningham D, Cotter F, et al. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma.Lancet. 1997;349:1137–1141.
Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.Blood. 1999;94:1840–1847.
Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.N Engl J Med. 2003;348:1764–1775.
Wierda WG, O’Brien S, Faderl S, et al. Improved survival in patients with relapsed-refractory chronic lymphocytic leukemia (CLL) treated with fludarabine, cyclophosphamide, and rituximab (FCR) combination [abstract].Blood. 2003;102:100a. Abstract 373.
Hainsworth JD, Litchy S, Barton JH, et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network.J Clin Oncol. 2003;21:1746–1751.
Tsang RW, Gospodarowicz MK, Pintilie M, et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome.J Clin Oncol. 2003;21:4157–4164.
Thieblemont C, Berger F, Dumontet C, et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed.Blood. 2000;95:802–806.
Zucca E, Conconi A, Roggero E, Ascani S, Campo E, Capella C. Non-gastric MALT lymphomas: a survey of 369 European patients: the International Extranodal Lymphoma Study Group (IELSG) [abstract].Ann Oncol. 2000;11:4499. Abstract 4440.
Isaacson PG. Gastric MALT lymphoma: from concept to cure.Ann Oncol. 1999;10:637–645.
Fischbach W, Goebeler-Kolve M, Starostik P, Greiner A, Muller-Hermelink HK. Minimal residual low-grade gastric MALT-type lymphoma after eradication ofHelicobacter pylori.Lancet. 2002;360:547–548.
Schetelig J, Thiede C, Bornhauser M, et al. Evidence of a graft- versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplan- tation: the Cooperative German Transplant Study Group.J Clin Oncol. 2003;21:2747–2753.
Liu H, Ruskon-Fourmestraux A, Lavergne-Slove A, et al. Resis- tance of t(11;18) positive gastric mucosa-associated lymphoid tis- sue lymphoma toHelicobacter pylori eradication therapy.Lancet. 2001;357:39–40.
Beutler E. Cladribine (2-chlorodeoxyadenosine).Lancet. 1992;340:952–956.
Carson DA, Kaye J, Seegmiller JE. Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphory- lase deficiency: possible role of nucleoside kinase(s).Proc Natl AcadSci USA. 1977;74:5677–5681.
Carson DA, Wasson DB, Kaye J, et al. Deoxycytidine kinase- mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo.Proc Natl Acad Sci USA. 1980;77:6865–6869.
Piro LD, Carrera CJ, Carson DA, Beutler E. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine.N Engl J Med. 1990;322:1117–1121.
Tallman MS, Hakimian D, Variakojis D, et al. A single cycle of 2-chlorodeoxyadenosine results in complete remission in the major- ity of patients with hairy cell leukemia.Blood. 1992;80:2203–2209.
Juliusson G, Liliemark J. High complete remission rate from 2-chloro-2′-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count.J Clin Oncol. 1993;11:679–689.
Saven A, Lemon RH, Kosty M, Beutler E, Piro LD. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia.J Clin Oncol. 1995;13:570–574.
Barton K, Larson RA, O’Brien S, Ratain MJ. Rapid response of B-cell prolymphocytic leukemia to 2-chlorodeoxyadenosine.J Clin Oncol. 1992;10:1821.
Kay AC, Saven A, Carrera CJ, et al. 2-Chlorodeoxyadenosine treat- ment of low-grade lymphomas.J Clin Oncol. 1992;10:371–377.
Hoffman M, Tallman MS, Hakimian D, et al. 2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin’s lymphoma.J Clin Oncol. 1994;12:788–792.
Saven A, Emanuele S, Kosty M, Koziol J, Ellison D, Piro L. 2-Chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin’s lymphoma.Blood. 1995;86:1710–1716.
Tobinai K, Ogura M, Hotta T, et al. Phase I study of cladribine (2-chlorodeoxyadenosine) in lymphoid malignancies: Cladribine Study Group.Jpn J Clin Oncol. 1997;27:146–153.
Tobinai K, Kohno A, Shimada Y, et al. Toxicity grading criteria of the Japan Clinical Oncology Group: the Clinical Trial Review Committee of the Japan Clinical Oncology Group.Jpn J Clin Oncol. 1993;23:250–257.
Cheson BD, Vena DA, Foss FM, Sorensen JM. Neurotoxicity of purine analogs: a review.J Clin Oncol. 1994;12:2216–2228.
Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma: a report from the Lymphoma Study Group (1984-87).Br J Haematol. 1991;79:428–437.
Saven A, Carrera CJ, Carson DA, Beutler E, Piro LD. 2-Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-cell lymphoma.Blood. 1992;80:587–592.
O’Brien S, Kurzrock R, Duvic M, et al. 2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders.Blood. 1994;84:733–738.
Kuzel TM, Hurria A, Samuelson E, et al. Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma [see comments].Blood. 1996;87:906–911.
Seto S, Carrera CJ, Kubota M, Wasson DB, Carson DA. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes.J Clin Invest. 1985;75:377–383.
Tobinai K, Uike N, Saburi Y, et al. Phase II study of cladribine (2-chlorodeoxyadenosine) in relapsed or refractory adult T-cell leukemia-lymphoma.Int J Hematol. 2003;77:512–517.
Tobinai K, Kobayashi Y, Morishima Y. Prolonged cytopenia and myelodysplastic syndrome after cladribine treatment in relapsed patients with indolent non-Hodgkin’s lymphoma: results of Japanese phase II study [abstract].Proc Am Soc Clin Oncol. 2001;20: 2228b. Abstract 2664.
Cheson BD, Vena DA, Barrett J, Freidlin B. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias.J Clin Oncol. 1999;17:2454–2460.
Rummel MJ, Chow KU, Jager E, et al. Intermittent 2-hour-infusion of cladribine as first-line therapy or in first relapse of progressive advanced low-grade and mantle cell lymphomas.Leuk Lymphoma. 1999;35:129–138.
Hickish T, Serafinowski P, Cunningham D, et al. 2-Chlorodeoxyadenosine: evaluation of a novel predominantly lymphocyte selective agent in lymphoid malignancies.Br J Cancer. 1993;67:139–143.
Dimopoulos MA, Weber D, Delasalle KB, Keating M, Alexanian R. Treatment of Waldenstrom’s macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: identification of prognostic factors.Ann Oncol. 1995;6:49–52.
Liliemark J, Juliusson G Cellular pharmacokinetics of 2-chloro-2-deoxyadenosine nucleotides: comparison of intermittent and continuous intravenous infusion and subcutaneous and oral administration in leukemia patients.Clin Cancer Res. 1995;1:385–390.
Liliemark J, Albertioni F, Hassan M, Juliusson G. On the bioavailability of oral and subcutaneous 2-chloro-2-deoxyadenosine in humans: alternative routes of administration.J Clin Oncol. 1992;10: 1514–1518.
Juliusson G, Heldal D, Hippe E, et al. Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia.J Clin Oncol. 1995;13:989–995.
Goodman GR, Burian C, Koziol JA, Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine.J Clin Oncol. 2003;21:891–896.
Kurzrock R, Strom SS, Estey E, et al. Second cancer risk in hairy cell leukemia: analysis of 350 patients.J Clin Oncol. 1997;15:1803–1810.
Chow KU, Rummel MJ, Weidmann E, et al. Induction of apoptosis by 2-chloro-2-deoxyadenosine (2-CdA) alone and in combination with other cytotoxic drugs: synergistic effects on normal and neoplastic lymphocytes by addition of doxorubicin and mitoxantrone.Leuk Lymphoma. 2000;36:559–567.
Saven A, Lee T, Kosty M, Piro L. Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin’s lymphoma.J Clin Oncol. 1996;14:2139–2144.
Betticher DC, von Rohr A, Ratschiller D, et al. Fewer infections, but maintained antitumor activity with lower-dose versus standard-dose cladribine in pretreated low-grade non-Hodgkin’s lymphoma.J Clin Oncol. 1998;16:850–858.
Betticher DC, Ratschiller D, Hsu Schmitz SF, et al. Reduced dose of subcutaneous cladribine induces identical response rates but decreased toxicity in pretreated chronic lymphocytic leukaemia: Swiss Group for Clinical Cancer Research (SAKK).Ann Oncol. 1998;9:721–726.
Robak T, Gora-Tybor J, Urbanska-Rys H, Krykowski E. Combination regimen of 2-chlorodeoxyadenosine (cladribine), mitoxantrone and dexamethasone (CMD) in the treatment of refractory and recurrent low grade non-Hodgkin’s lymphoma.Leuk Lymphoma. 1999;32:359–363.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Armitage, J.O., Tobinai, K., Hoelzer, D. et al. Treatment of Indolent Non-Hodgkin’s Lymphoma with Cladribine as Single-Agent Therapy and in Combination with Mitoxantrone. Int J Hematol 79, 311–321 (2004). https://doi.org/10.1532/IJH97.04050
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1532/IJH97.04050